Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 3 of 7 for:    dalbavancin

A P3 Comparator Trial in Community Acquired Bacterial Pneumonia

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified October 2014 by Durata Therapeutics, Inc.
Sponsor:
Information provided by (Responsible Party):
Durata Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT02269644
First received: October 7, 2014
Last updated: October 20, 2014
Last verified: October 2014
  Purpose

This study will be a double-blind, randomized, multicenter trial to assess the safety and efficacy of a single 1500 mg IV dose of dalbavancin plus a single 500 mg IV dose of azithromycin in comparison to an approved antibiotic regimen of linezolid 600 mg every 12 hours for 10-14 days plus a single 500 mg IV dose of azithromycin for the treatment of Community Acquired Bacterial Pneumonia.


Condition Intervention Phase
Community Acquired Pneumonia
Drug: Dalbavancin
Drug: Linezolid
Drug: Linezolid Placebo
Drug: Azithromycin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Double-blinded, Randomized, Comparator Trial of the Safety and Efficacy of a Single Dose of Dalbavancin to Twice Daily Linezolid for the Treatment of Community Acquired Bacterial Pneumonia

Resource links provided by NLM:


Further study details as provided by Durata Therapeutics, Inc.:

Primary Outcome Measures:
  • Treatment Response of CABP Symptoms [ Time Frame: Change from Baseline to Day 4-5 (72-120 hours after randomization) ] [ Designated as safety issue: No ]
    Compare the efficacy of a single 1500 mg dose of intravenous dalbavancin plus azithromycin to the comparator regimen (linezolid plus azithromycin). Response will be based on resolution of symptoms; including chest pain, shortness of breath (difficulty breathing), frequency/severity of cough and amount of sputum production. Each of these symptoms will be assessed on a 4 point scale (absent, mild, moderate or severe). A patient will be defined as a clinical responder if there is at least a 1 point improvement in 2 or more of these symptoms at 72-120 hours after randomization compared to baseline.


Secondary Outcome Measures:
  • Efficacy of dalbavancin to the comparator regimen [ Time Frame: Change from baseline to Day 4-5 (72-120 hours after randomization, Day 14 and Day 28 ] [ Designated as safety issue: No ]
    Test the efficacy of dalbavancin to the comparator regimen using alternative outcome measures including:1) improvement at Day 4-5 in at least two of the following symptoms with no worsening in any of these symptoms of CABP compared to baseline: chest pain, frequency or severity of cough, amount of productive sputum, and difficulty breathing and improvement in vital signs (i.e. temperature, heart rate, respiratory rate or blood pressure); 2) clinical outcome (using primary response criteria) at Day 14; 3) Investigator Assessment of Outcome at Day 14 and Day 28, with success defined as complete resolution of symptoms and signs attributable to CABP and did not receive non-trial antibacterial drugs for treatment of CABP.4) all-cause mortality at Day 28

  • Safety Analysis [ Time Frame: Safety will be assessed at all time-points through Day 28 ] [ Designated as safety issue: Yes ]
    To test the safety profile of dalbavancin 1500 mg versus comparator. Safety will be assessed by means of physical examination and vital signs, collection of adverse, events and clinical laboratory tests through out the study.

  • Population Pharmacokinetics of a Single 1500 mg dose of dalbavancin including PK Measures AUC0-72 and PK PD index (AUC:MIC), The study PK-PD index and other demographics data will be pooled with other dalbavancin studies for a PK-PD analysis [ Time Frame: Baseline and four time points after the Day 1 infusion of blinded dalbavcin ] [ Designated as safety issue: No ]
    At selected sites the population PK profile of dalbavancin using a sparse sampling approach. Samples will be collected at baseline and after the 1st dose at 1 hour, 18 hours, 23 hours and 36-48 hours from subjects in both treatment arms; only samples from patients receiving dalbavancin will be analyzed. The study will remain blinded, regardless of whether or not any individual patient chooses to participate in the population PK sampling.


Estimated Enrollment: 438
Study Start Date: November 2014
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dalbavancin
Dalbavancin randomized subjects will receive one dose of dalbavancin 1500 mg IV over 30 minutes on Day 1 plus azithromycin 500 mg IV on Day 1. Dalbavancin dose will be adjusted for subjects with significant renal insufficiency who are not receiving regular hemodialysis. All patients in the dalbavancin group will receive placebo linezolid infusions or tablets to maintain the blinding. Dalbavancin dose will be adjusted for subjects with significant renal insufficiency who are not receiving regular hemodialysis
Drug: Dalbavancin
dalbavancin 1500 mg IV over 30 minutes on Day 1
Other Name: Dalvance
Active Comparator: Linezolid
Linezolid randomized subjects will receive linezolid 600 mg every 12 hours for a minimum of 10 days, and a maximum of 14 days. All patients will receive at least one IV dose of linezolid initially plus azithromycin 500 mg IV only on Day 1. Subjects then may then be switched to oral linezolid at the discretion of the investigator, if clinical improvement in the signs and symptoms of pneumonia is observed, to complete the 10-14 day course of therapy,. No dose adjustment is required for renal insufficiency.
Drug: Linezolid
linezolid 600 mg every 12 hours for a minimum of 10 days and a maximum of 14 days
Other Name: Zyvox
Linezold Placebo IV and Oral Capsules
Dalbavancin randomized subjects after the 1st dose on Day 1 will receive placebo linezolid every 12 hours for a minimum of 10 days and a maximum of 14 days. Dalbavancin randomized subjects may be switched to oral linezolid placebo therapy to complete the 10-14 day course of therapy.
Drug: Linezolid Placebo
Dalbavancin randomized subjects after Day 1, 1st dose will receive linezolid placebo every 12 hours for a minimum of 10 days and a maximum of 14 days
Azithromycin
Dalbavancin and linezolid randomized subjects on Day 1, 1st dose will also receive 500 mg of IV azithromycin
Drug: Azithromycin
Dalbavancin and linezolid randomized subjects on Day 1, 1st dose receive 500 mg of IV azithromycin

Detailed Description:

This study will be a double-blind, randomized, multicenter trial to assess the safety and efficacy of a single 1500 mg IV dose of dalbavancin plus a single 500 mg IV dose of azithromycin in comparison to an approved antibiotic regimen of linezolid 600 mg every 12 hours for 10-14 days plus a single 500 mg IV dose of azithromycin for the treatment of CABP. Adult patients who meet all inclusion and none of the exclusion criteria will be randomized to one of the two treatment arms. Dosing will commence on Day 1, and all patients will receive a minimum of 10 days of therapy. Patients will be assessed on Day 1, Day 4-5, Day 7, Day 14 (End of Therapy, EOT), and Day 28 (Follow up).

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adults aged 18 to 85, inclusive
  2. Has given written, informed consent
  3. Has acute illness with onset within previous 7 days
  4. Has at least 2 of the following symptoms:

    • Difficulty breathing or shortness of breath
    • Cough
    • Production of purulent sputum
    • Pleuritic chest pain
  5. Has at least 2 vital sign abnormalities:

    • Fever (> 38°C or < 35°C)
    • Hypotension (systolic BP < 90 mm Hg)
    • Tachycardia (> 100 beats /min)
    • Tachypnea (> 24 breaths /min)
  6. Has at least one other clinical or laboratory abnormalities:

    • Hypoxemia (room air SaO2 < 90% )
    • Clinical evidence of pulmonary consolidation
    • Elevated WBC count or neutropenia (> 12,000/mm3 or < 4,000/mm3)
  7. Has new lobar or multi-lobar infiltrates on chest radiograph
  8. Has CURB-65 risk category 1 to 4. Patients with CURB-65 risk category 1 will be limited to 20% of the total patient population

Exclusion Criteria:

  1. Contra-indication to the administration of any of the study treatments, such as hypersensitivity to any of the glycopeptide agents, beta-lactam agents, linezolid or macrolide antibiotics, or current or recent (within 2 weeks) use of MAO inhibitors or serotonergic antidepressants (within 5 weeks for fluoxetine) (see Section 5.5.1)
  2. Has received antibiotic therapy in the 4 days prior to screening, with the following exception: up to 25% of patients may have received a single dose of a short acting (half life < 8 hours) antibiotic
  3. Has aspiration pneumonia
  4. Has hospital acquired or ventilator associated pneumonia, or healthcare associated pneumonia, or 2 or more days in hospital in the previous 90 days
  5. Has cystic fibrosis or known or suspected Pneumocystis pneumonia or known or suspected active tuberculosis
  6. Females of child-bearing potential who are unable to take adequate contraceptive precautions, have a positive pregnancy result within 24 hours prior to study entry, are known to be pregnant, or are currently breastfeeding an infant
  7. Has primary or metastatic lung cancer
  8. Has known bronchial obstruction or a history of post-obstructive pneumonia
  9. Requires admission to ICU at baseline
  10. Has empyema requiring drainage
  11. Infection due to an organism known prior to study entry to be resistant to either treatment regimen
  12. Has known or suspected infection due solely to an atypical pathogen such as Mycoplasma sp., Chlamydia sp. or Legionella sp. or positive Legionella urinary antigen at baseline
  13. Absolute neutrophil count < 500 cells/mm3
  14. Known or suspected human immunodeficiency virus (HIV) infected patients with a CD4 cell count < 200 cells/mm3 or with a past or current acquired immunodeficiency syndrome (AIDS)-defining condition and unknown CD4 count
  15. Patients with a recent bone marrow transplant (in post-transplant hospital stay)
  16. Patients receiving oral steroids > 40 mg prednisolone per day (or equivalent) or receiving immunosuppressant drugs after organ transplantation
  17. Patients with a rapidly fatal illness, who are not expected to survive for 3 months
  18. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
  19. Has participated in another trial of an investigational pharmaceutical product in the 30 days prior to enrollment
  20. Prior participation in this trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02269644

Contacts
Contact: James A Hazel, BSN 203 871 4621 jhazel@duratatx.com
Contact: James Baldassarre, MD 203 871 4613 jbaldassarre@duratatx.com

Locations
United States, Montana
Mercury Street Medical Group
Butte, Montana, United States, 59701
Sponsors and Collaborators
Durata Therapeutics, Inc.
  More Information

No publications provided

Responsible Party: Durata Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT02269644     History of Changes
Other Study ID Numbers: DUR001-305
Study First Received: October 7, 2014
Last Updated: October 20, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Dalbavancin
Pneumonia
Pneumonia, Bacterial
Bacterial Infections
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Linezolid
Teicoplanin
Anti-Bacterial Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Synthesis Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014